Gene-environment and Gene-gene Interaction in the Determination of Plasma Homocysteine Levels in Healthy Middle-aged Men

Vanessa Dekou; Vilmundur Gudnason; Emma Hawe; George J. Miller; David Stansbie; Steve E. Humphries

doi:10.1055/s-0037-1612906

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2001; 85(01): 67-74
DOI: 10.1055/s-0037-1612906

Review Article

Schattauer GmbH

Gene-environment and Gene-gene Interaction in the Determination of Plasma Homocysteine Levels in Healthy Middle-aged Men

Vanessa Dekou

¹Cardiovascular Genetics, Department of Medicine, University College London Medical School, The Rayne Institute, London

,

Vilmundur Gudnason

¹Cardiovascular Genetics, Department of Medicine, University College London Medical School, The Rayne Institute, London

,

Emma Hawe

¹Cardiovascular Genetics, Department of Medicine, University College London Medical School, The Rayne Institute, London

,

George J. Miller

²Medical Research Council Epidemiology and Medical Care Unit, Wolfson Institute of Preventive Medicine, London

,

David Stansbie

³Department of Chemical Pathology, Bristol Royal Infirmary, Bristol, UK

,

Steve E. Humphries

¹Cardiovascular Genetics, Department of Medicine, University College London Medical School, The Rayne Institute, London

› Institutsangaben

Abstract

Summary

Healthy middle-aged men (n = 1470) from eight general practices across Britain were examined for plasma total homocysteine levels and genotyped for the A222V polymorphism in the methylene-tetrahydrofolate (MTHFR) gene, the 68 bp insertion polymorphism in exon 8 of the cystathionine b synthase (CBS) gene and the D919G polymorphism in the methionine synthase (MS) gene. The median value for plasma homocysteine was 11.90 μmol/l (25–75% Interquartile range 10.10-14.20) for the whole sample. Smokers had significantly higher homocysteine levels than non-smokers (12.90 vs 11.70 μmol/l and p <0.00005) and levels significantly differed according to folate (p-value <0.00005), with men in the lowest quartile of folate having the highest median homocysteine levels. Genotype at all three loci was associated with differences in plasma homocysteine level. Individuals homozygous for the MTHFR V222 allele had 1.6 μmol/l higher median homocysteine levels when compared to the other two genotypes (p <0.00005), while for the CBS and MS genes, individuals carrying one or more of the rare alleles had lower median homocysteine than individuals homozygous for the common allele (0.80 μmol/l, p <0.03, and 0.70 μmol/l, p <0.04 respectively). The raising effect associated with homozygosity for the V222 allele was greater in men in the lowest quartile of folate (interaction between folate and genotype p = 0.02), but none of the genotype effects was significantly modulated by B12 levels. While the raising effects of V222 and MS D919 homozygosity on homocysteine level were essentially additive, the homocysteine lowering effect associated with the CBS 68bp allele was seen most strongly in men homozygous for the V222 allele (MTHFR-CBS genotype interaction p = 0.03) and the D919 allele (MS-CBS interaction p = 0.09). Age, folate, B12 and smoking explained 13.48% of the variance while the three genotypes combined and with interaction terms explained only an additional 2.63%. This interaction between CBS genotype and MTHFR and MS genotype points to a key role of the CBS transulphuration pathway in the metabolism of homocysteine that may be particularly important as a compensatory mechanism in subjects with low dietary folate.

Keywords

MTHFR - CBS - methionine synthase - homocysteine - folate

Volltext

Referenzen

References
1 Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr 1998; 157 Suppl 2 S40-4.
2 Finkelstein JD, Harris BJ, Martin JJ, Kyle WE. Regulation of hepatic betaine-homocysteine methyltransferase by dietary methionine. Biochem Biophys Res Commun 1982; 108 (01) 344-8.
3 Mudd SH, Levy HL. Plasma homocyst(e)ine or homocysteine?. N Engl J Med 1995; 333 (05) 325.
4 Finkelstein JD, Martin JJ. Methionine metabolism in mammals. Distribution of homocysteine between competing pathways. J Biol Chem 1984; 259 (15) 9508-13.
5 Mudd SH, Poole JR. Bile methyl balances for normal humans on various dietary regimens. Metabolism 1975; 24 (06) 721-35.
6 Kutzback C, Stokstad ELR. Mammalian methylenetetrahydrofolate reductase. Partial purification, properties, and inhibition by S-adenosylmethionine. Biochim Biophys Acta 1971; 250 (03) 459-77.
7 Finkelstein JD, Harris B. Methionine metabolism in mammals: S-adenosylhomocysteine hydrolase in rat intestinal mucosa. Arch Biochem Biophys 1975; 171 (01) 282-6.
8 Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
9 Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma Reis RJ, Boers GH, Sheahan RG, Israelsson B. et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project JAMA 1997; 277: 1775-81.
10 Duell PB, Malinow MR. Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease. Curr Opinion Lip 1997; 8: 28-34.
11 De Jong SC, Stehouwer CDA, van den Berg M, Vischer UM, Rauwerda JA, Emeis JJ. Endothelial marker proteins in hyperhomocysteinemia. Thromb Haemost 1997; 78: 1332-7.
12 Upchurch GR, Welch GN, Fabian AJ, Pigazzi A, Keaney JF, Loscalzo J. Stimulation of endothelial nitric oxide production by homocyst(e)ine. Athero 1997; 132: 177-85.
13 Legnani C, Palareti G, Grauso F, Sassi S, Grossi G, Piazzi S, Bernardi F, Marchetti G, Ferraresi P, Coccheri S. Hyperhomocyst(e)inemia and a common methylenetetrahydrofolate reductase mutation (Ala223Val MTHFR) in patients with inherited thrombophilic coagulation defects. Arterioscler Thromb Vasc Biol 1997; 17 (11) 2924-9.
14 Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocysteinemia, factor V Leiden and risk of future venous thromboembolism. Circulation 1997; 95: 1777-82.
15 Ray JG. Meta analysis of hyperhomocysteinemia as a risk factor for venous thrombosis disease. Arch Intern Med 1998; 158: 2101-16.
16 Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-21.
17 Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP. et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
18 Brattstrom L WD, Ohrvik J. Common Methylenetetrahudrofolate reductase gene mutation leads to hyperhomocysteinaemia but not to vascular disease: the result of a meta-analysis. Circulation 1998; 23: 2520-6.
19 Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. EARS group. Atherosclerosis 1998; 136: 347-54.
20 Fletcher O, Kessling AM. MTHFR association with arteriosclerotic vascular disease?. Hum Genet 1998; 103: 11-21.
21 Sebastio G, Sperandeo MP, Panico M, de Franchis R, Kraus JP, Andria G. The molecular basis of homocystinuria due to cystathionine beta-synthase deficiency in Italian families, and report of four novel mutations. Am J Hum Genet 1995; 56: 1324-33.
22 Tsai MY, Bignell M, Schwichtenberg K, Hanson NQ. High prevalence of a mutation in the cystathionine beta-synthase gene. Am J Hum Genet 1996; 59: 1262-7.
23 Sperandeo MP, Candito M, Sebastio G, Rolland MO, Turc Carel C, Giudicelli H, Dellamonica P, Andria G. Homocysteine response to methionine challenge in four obligate heterozygotes for homocystinuria and relationship with cystathionine beta-synthase mutations. J Inherit Metab Dis 1996; 19: 351-6.
24 Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, Eydoux P, Rosenblatt DS, Rozen R, Gravel RA. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996; 5: 1867-74.
25 van der Put NM, van der Molen EF, Kluijtmans LA, Heil SG, Trijbels JM, Eskes TK, Van Oppenraaij Emmerzaal D, Banerjee R, Blom HJ. Sequence analysis of the coding region of human methionine synthase: relevance to hyperhomocysteinaemia in neural-tube defects and vascular disease. Quart J Med 1997; 90: 511-7.
26 Morrison K, Papapetrou C, Hol FA, Mariman EC, Lynch SA, Burn J, Edwards YH. Susceptibility to spina bifida; an association study of five candidate genes. Ann Hum Genet 1998; 62: 379-96.
27 Morita H KH, Sugiyama T. Polymorhpism of the Methionine Synthase Gene. Association with homocysteine metabolism and late onset vascular diseases in the Japanese population. Arterioscler Thromb Vasc Biol 1999; 298-302.
28 Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost 1996; 75: 767-71.
29 Fiskerstrand T, Refsum H, Kvalheim G, Ueland PM. Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin Chem 1993; 39: 263-71.
30 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
31 De Stefano V, Dekou V, Nicaud V, Chasse JF, London J, Stansbie D, Humphries SE, Gudnason V. Linkage disequilibrium at the cystathionine B synthase (CBS) locus and the association between genetic variation at the CBS locus and plasma levels of homocysteine. Ann Hum Genet 1998; 481-90.
32 Day IN, Humphries SE. Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal Biochem 1994; 222: 389-95.
33 Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvale G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274: 1526-33.
34 McPhillips JB, Eaton CB, Gans KM, Derby CA, Lasater TM, McKenney JL, Carleton RA. Dietary differences in smokers and nonsmokers from two southeastern New England communities. J Am Diet Assoc 1994; 94: 287-92.
35 Malinow MR, Nieto FJ, Kruger WD, Duell PB, Hess DL, Gluckman RA, Block PC, Holzgang CR, Anderson PH, Seltzer D. et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol 1997; 17: 1157-62.
36 Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
37 Nelen WL, Blom HJ, Thomas CM, Steegers EA, Boers GH, Eskes TK. Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages. J Nutr 1998; 128 (08) 1336-41.
38 Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly RK, Hess DL, Psaty BM, Longstreth Jr WT, Koepsell TD, Raghunathan TE, Reitsma PH. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997; 96 (02) 412-7.
39 Molloy AM, Daly S, Mills JL, Kirke PN, Whitehead AS, Ramsbottom D, Conley MR, Weir DG, Scott JM. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet 1997; 349 9065 1591-3.
40 Kozich V, Kraus E, de Franchis R, Fowler B, Boers GH, Graham I, Kraus JP. Hyperhomocysteinemia in premature arterial disease: examination of cystathionine beta-synthase alleles at the molecular level. Hum Mol Genet 1995; 4: 623-9.
41 Wang XL, Duarte N, Cai H, Adachi T, Sim AS, Cranney G, Wilcken DE. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. Atheroscler 1999; 146 (01) 133-40.
42 Tsai MY, Yang F, Bignell M, Aras Ö, Hanson NQ. Relation between plasma homocysteine concentration, the 844ins68 variant of the cystathionine β-synthase gene, and pyridoxal-5’-phosphate concentration. Molec Genet & Metabol 1999; 67 (04) 352-6.
43 Dudman NP, Wilcken DE, Wang J, Lynch JF, Macey D, Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler Thromb 1993; 13: 1253-60.
44 Loehrer FM, Angst CP, Haefeli WE, Jordan PP, Ritz R, Fowler B. Low whole-blood S-adenosylmethionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease. Arterioscler Thromb Vasc Biol 1996; 16: 727-33.
45 Cai H, Wang X, Colagiuri S, Wilcken DE. Methionine synthase D919G mutation in type 2 diabetes and its relation to vascular events. Diabetes Care 1998; 21: 1774-5.
46 Guttormsen AB, Ueland PM, Nesthus I, Nygard O, Schneede J, Vollset SE, Refsum H. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hordaland Homocysteine Study Kinetics of total plasma homocysteine in subjects with hyperhomocysteinemia due to folate or cobalamin deficiency. J Clin Invest 1996; 63: 194-202.
47 Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett WC, Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94: 2410-6.
48 Harmon DL, Woodside JV, Yarnell JW, McMaster D, Young IS, McCrum EE, Gey KF, Whitehead AS, Evans AE. The common ’thermolabile’ variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. Quart. J Med 1996; 89: 571-7.